Exchange Traded Concepts to Close and Liquidate the Range Cancer Therapeutics ETF

OKLAHOMA CITY, May 8, 2025 /PRNewswire/ -- The Board of Trustees of ETF Series Solutions, upon a recommendation from Exchange Traded Concepts, LLC, the investment adviser to the Range Cancer Therapeutics ETF (the "Fund"), has determined to close and liquidate the Fund immediately after the close of business on May 27, 2025 (the "Liquidation Date"). Shares of the Fund are listed on The Nasdaq Stock Market LLC.

Effective on or about May 13, 2025, the Fund will begin liquidating its portfolio assets. This will cause the Fund to increase its cash holdings and deviate from the investment objective and strategies stated in the Fund's prospectus.

The Fund will no longer accept orders for new creation units after the close of business on the business day prior to the Liquidation Date, and trading in shares of the Fund will be halted prior to market open on the Liquidation Date. Prior to the Liquidation Date, shareholders may only be able to sell their shares to certain broker-dealers, and there is no assurance that there will be a market for the Fund's shares during that time period. Customary brokerage charges may apply to such transactions.

On or about the Liquidation Date, the Fund will liquidate its assets and distribute cash pro rata to all remaining shareholders. These distributions are taxable events. Distributions made to shareholders should generally be treated as received in exchange for shares and will therefore generally give rise to a capital gain or loss depending on a shareholder's tax basis. Shareholders should contact their tax advisor to discuss the income tax consequences of the liquidation. As calculated on the Liquidation Date, the Fund's net asset value will reflect the costs of closing the Fund, if any. Once the distributions are complete, the Fund will terminate. Proceeds of the liquidation will be sent to shareholders promptly after the Liquidation Date.

For additional information, please call 1-800-617-0004.

Please retain this Supplement with your Summary Prospectus, Prospectus, and SAI for future reference.

The Range Cancer Therapeutics ETF is offered by prospectus. Carefully consider the investment objectives, risks, charges, and expenses. This and other important information can be found in the CNCR ETF prospectus, which should be read carefully before investing and can be obtained by visiting www.rangeetfs.com/cncr, or by calling 1-800-617-0004.

All investing involves risk, and asset allocation and diversification do not guarantee a profit or protection against a loss. The investment return and principal value of an investment will fluctuate so that an investor's shares, when redeemed, might be worth more or less than their original cost. ETFs are subject to risks similar to those of stocks, as well as other risks specific to the particular ETF.

ETF shares are traded on exchanges and are traded and priced throughout the trading day. ETFs permit an investor to purchase a selling interest in a portfolio of stocks throughout the trading day. Because ETFs trade on an exchange, ETF shares are bought and sold at market price (not NAV). The prices of ETFs may sometimes vary significantly from the NAVs of an ETFs' underlying securities. Brokerage commissions will reduce returns.

The Fund is a recently organized investment company with no operating history. As a result, prospective investors have no track record or history on which to base their investment decision. Moreover, investors will not be able to evaluate the Fund against one or more comparable funds on the basis of relative performance until the Funds has established a track record.

Exchange Traded Concepts, LLC serves as the investment advisor to the Fund. The Fund is distributed by Quasar Distributors, LLC. Quasar is not affiliated with Exchange Traded Concepts, LLC.

Distributor: Quasar Distributors, LLC.

View original content:https://www.prnewswire.com/news-releases/exchange-traded-concepts-to-close-and-liquidate-the-range-cancer-therapeutics-etf-302449405.html

SOURCE Exchange Traded Concepts, LLC